Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 1st Preview)
-
Moderna wins EU backing: combo flu–COVID vaccine cleared by CHMP
European regulators’ human medicines committee recommended approval of Moderna’s mCombriax, a combined influenza and COVID-19 mRNA vaccine, clearing a major regulatory hurdle for the product in people aged 50 and older. The EMA’s CHMP found the vaccine produced adequate antibody responses against both viruses, according to the company and regulator statements. Moderna CEO Stéphane Bancel highlighted the milestone as the world’s first flu–COVID combination vaccine and said the decision will move to the European Commission for final authorization. The recommendation follows a fraught regulatory path in the U.S., where Moderna faced additional data requests and delayed review timelines from the FDA. The CHMP’s positive opinion could accelerate market access in Europe even as questions linger about U.S. prospects. For vaccine manufacturers and payers, an approved combination shot would change seasonal immunization logistics and product positioning. The recommendation was reported by the EMA and covered in major outlets including Reuters and company releases.
-
BioNTech advances B7-H3 ADC: phase 3 start in prostate cancer
BioNTech and partner DualityBio moved their B7-H3–targeting antibody–drug conjugate into a phase 3 trial for metastatic castration‑resistant prostate cancer (mCRPC) after encouraging phase 1/2 data, the companies said. The program is positioned against a competing Merck & Daiichi Sankyo ADC but aims to run a pivotal study roughly half the size of the rival program, a strategy that could shorten timelines and reduce costs if regulators accept the design. BioNTech is leveraging clinical efficacy signals to accelerate late‑stage testing in a crowded ADC field. The phase 3 launch reflects investor and partner appetite to back targeted cytotoxic payload delivery approaches in solid tumors; sources include company disclosures and industry reporting.
-
Atrium spins out RNA cardio programs — $270M bankroll
Atrium Therapeutics launched as a spinout carrying Avidity Biosciences’ cardiac RNA delivery programs, debuting with about $270 million in cash to advance therapies for rare inherited cardiomyopathies. The company was formed after Novartis acquired Avidity; Atrium is led by former Avidity executives including CEO Kathleen Gallagher and chair Sarah Boyce. Its initial pipeline targets PRKAG2 syndrome and PLN cardiomyopathy and includes two programs with paths to the clinic. Atrium’s launch preserves RNA delivery assets Avidity did not include in the Novartis purchase and underscores continued investor belief in tissue‑targeted RNA modalities beyond the liver. The spinout was reported by MedCity News and company statements and positions Atrium to pursue rare cardiac indications with limited treatment options.
-
Generate raises $400M: AI‑driven protein design firm prices IPO
Generate Biomedicines priced an IPO that raised roughly $400 million to fund pivotal trials for its severe asthma program and further develop its programmable‑biology platform. Founded by Flagship Pioneering, Generate’s lead asset targets TSLP and the company positions its AI/ML protein design capabilities as a differentiator for less‑frequent dosing biologics. The offering closed with strong demand but shares dipped in the aftermarket, a mixed signal about investor appetite for platform‑driven biotechs. The financing provides material runway for pivotal testing and highlights continued public-market interest in AI‑augmented drug design despite broader biotech volatility. Reporting sources include MedCity News and contemporaneous IPO filings and coverage.
-
Abbott floats $20B notes to fund Exact Sciences buy — debt package unveiled
Abbott disclosed a $20 billion senior notes offering intended to help finance its pending $23 billion acquisition of Exact Sciences. The debt package spans multiple tranches and maturities and names Morgan Stanley, Barclays, BofA Securities and J.P. Morgan as underwriters. Abbott said proceeds will also repay certain Exact Sciences indebtedness and support general corporate purposes. The financing move formalizes the balance‑sheet plan behind one of the sector’s largest diagnostics deals and signals confidence in completing the transaction in the second quarter of 2026 following shareholder approval. The disclosure comes from SEC filings reviewed by financial press.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.